Among patients with hormone receptor-positive breast cancer treated with an aromatase inhibitor plus Ibrance (palbociclib), those who displayed a rising ESR1 mutation detected in their blood before disease progression doubled their median progression-free survival following a switch to Faslodex (fulvestrant) plus Ibrance, according to results from the phase III PADA-1 clinical trial.
To access this subscriber-only content please log in or renew your subscription.
Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.
Login Subscribe
Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.
Login Subscribe